Dissolution rate-limited absorption and complete bioavailability of roquinimex in man

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 7, 1999, Pages 347-354

  Strandgården, Kerstin ^a   Höglund, Peter ^b   Nordle, Örjan ^c   Polacek, Jiri ^c   Wännman, Hans ^c   Gunnarsson, Per Olov ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Active Biotech Research AB   (Sweden)

Author keywords

Bioavailability; Compartmental; Loo Riegelman; Pharmacokinetics; Roquinimex

Indexed keywords

ROQUINIMEX;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; ENTEROHEPATIC CIRCULATION; FEMALE; HUMAN; MALE; NORMAL HUMAN; PLASMA CLEARANCE; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HUMANS; HYDROXYQUINOLINES; INTESTINAL ABSORPTION; MALE; PROTEIN BINDING; SOLUBILITY;

EID: 17144465685     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199910)20:7<347::AID-BDD194>3.0.CO;2-0     Document Type: Article

References (19)

1. Tarkowski A, Gunnarsson K, Nilsson LÅ, Lindholm L, Stålhandske T. Successful treatment of autoimmunity in MRL/1 mice with LS 2616, a new immunomodulator. Arthritis Rheum 1986; 29: 1405-1409.
2. Tarkowski A, Gunnarsson K, Stålhandske T. Effects of LS 2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice. Immunology 1986; 59: 589-594.
3. Gross DJ, Sidi H, Weiss L, Kalland T, Rosenmann E, Slavin S. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologia 1994; 37(12): 1195-1201.
4. Karussis DM, Lehmann D, Slavin S, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, Kalland T, Abramsky O. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 1993; 90: 6400-6404.
5. Lehmann D, Karussis DM, Fluresco D, Mizrachi-Koll R, Ovadia H, Shezen E, Kalland T, Abramsky O. Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J Neoroimmunol 1997; 74(1-2): 102-110.
6. Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, Åström M, Gjörstrup P, Ekholm S. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47: 895-900.
7. Karussis DM, Meiner Z, Lehmann D, Gomori JM, Schwarz A, Linde A, Abramsky O. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996; 47: 341-346.
8. Nived O, Sturfelt G, Nilsson B, Termander B, Gunnarsson PO, Strandgården K, Wollheim F. Clinical pilot study of roquinimex (Linomide®) in patients with autoimmune disease. Int J Immunothenpy 1994; X(2): 49-59.
9. Bergh JCS, Tötterman TH, Termander BC, Strandgården K, Gunnarsson PO, Nilsson B. The first clinical pilot study of roquinimex (Linomide®) in cancer patients with special focus on immunological effects. Cancer Investigation 1997; 15(3): 204-211.
10. World Medical Association Declaration of Helsinki. Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964 and amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975; the 35th World Medical Assembly, Venice, Italy, October 1983; and the 41st World Medical Assembly, Hong Kong, September 1989.
11. Gibaldi M, Perrier D. Pharmacokinetics. New York: Dekker, 1982.
12. Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokin Biopharm 1980; 8: 165-176.
13. WinNonlin Professional. Version 1.5 User's Guide. Lexington, KY: Scientific Consulting Inc, 1997.
14. Akaike A. Posterior probabilities for choosing a regression model. Ann Instit Math Stat 1978; 30A: 9-14.
15. Wagner J. Pharmacokinetics for the Pharmaceutical Scientist. Lancaster, PA: Technomic Publishing Company, 1993.
16. Loo JCK, Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci 1968; 57(6): 918-928.
17. Rowland M, Tozer T. Clinical pharmacokinetics. Concepts and Application, 3rd Edition. USA: Williams & Wilkins Media, 1995.
18. Shepard TA, Reuning RH. An equation for the systemic availability of drugs undergoing simultaneous enterohepatic cycling, first-pass metabolism and intestinal elimination. Pharm Res 1987; 4(3): 195-199.
19. Wijnand HP. Pharmacokinetic model equations for the one-and two-compartment models with first-order processes in which the absorption and exponential elimination or distribution rate constants are equal. J Pharmacokin Biopharm 1988; 16(1): 109-128.